Хірургічне втручання у пацієнтів, які проходять антитромбоцитарну терапію 8 страница

585. Johansson BL, Souza DS, Bodin L, Filbey D, Loesch A, Geijer H, Bojo L. Slower progression­of atherosclerosis in vein grafts harvested with ’no touch’ technique compared­with conventional harvesting technique in coronary artery bypass grafting: an­angiographic and intravascular ultrasound study. Eur J Cardiothorac Surg 2010;38(4):­414–419

586. Deo SV, Shah IK, Dunlay SM, Erwin PJ, Locker C, Altarabsheh SE, Boilson BA,­Park SJ, Joyce LD. Bilateral internal thoracic artery harvest and deep sternal­wound infection in diabetic patients. Ann Thorac Surg 2013;95(3):862–869

587. SaMP, Ferraz PE, Escobar RR, Vasconcelos FP, Ferraz AA, Braile DM, Lima RC. Skeletonized­vs. pedicled internal thoracic artery and risk of sternal wound infection­after coronary bypass surgery: meta-analysis and meta-regression of 4817 patients Interact Cardiovasc Thorac Surg 2013;16(6):849–857

588. Sakic A, Chevtchik O, Kilo J, Schistek R, Mueller LC, Ulmer H, Grimm M,­Ruttmann E. Simple adaptations of surgical technique to critically reduce the risk­of postoperative sternal complications in patients receiving bilateral internal thoracic­arteries. Interact Cardiovasc Thorac Surg 2013;17(2):378–382

589. Lytle BW. Skeletonized internal thoracic artery grafts and wound complications J Thorac Cardiovasc Surg 2001;121(4):625–627

590. Wendler O, Hennen B, Markwirth T, Konig J, Tscholl D, Huang Q, Shahangi E,­Schafers HJ. T grafts with the right internal thoracic artery to left internal thoracic­artery vs. the left internal thoracic artery and radial artery: flow dynamics in the internal­thoracic artery main stem. J Thorac Cardiovasc Surg 1999;118(5):841–848

591. Taggart DP. Incomplete revascularization: appropriate and inappropriate. Eur J Cardiothorac­Surg 2012;41(3):542–543

592. Zimarino M, Curzen N, Cicchitti V, De Caterina R. The adequacy of myocardial­revascularization in patients with multivessel coronary artery disease. Int J Cardiol­2013;168(3):1748–1757

593. Ong AT, Serruys PW. Complete revascularization: coronary artery bypass graft­surgery vs. percutaneous coronary intervention. Circulation 2006;114(3):249–255

594. Farooq V, Serruys PW, Garcia–Garcia HM, Zhang Y, Bourantas CV, Holmes DR,­Mack M, Feldman T, Morice MC, Stahle E, James S, Colombo A, Diletti R,­Papafaklis MI, de Vries T, Morel MA, van Es GA, Mohr FW, Dawkins KD,­Kappetein AP, Sianos G, Boersma E. The negative impact of incomplete angiographic­revascularization on clinical outcomes and its association with total occlusions:­the SYNTAX (Synergy Between Percutaneous Coronary Intervention with­Taxus and Cardiac Surgery) trial. J Am Coll Cardiol 2013;61(3):282–294

595. Head SJ, Mack MJ, Holmes DR Jr., Mohr FW, Morice MC, Serruys PW,­Kappetein AP. Incidence, predictors and outcomes of incomplete revascularization­after percutaneous coronary intervention and coronary artery bypass grafting: a­subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg 2012;41(3):­535–541

596. Kim YH, Park DW, Lee JY, Kim WJ, Yun SC, Ahn JM, Song HG, Oh JH, Park JS,­Kang SJ, LeeSW, LeeCW, ParkSW, Park SJ. Impact of angiographic complete revascularization­after drug-eluting stent implantation or coronary artery bypass graft­surgery for multivessel coronary artery disease. Circulation 2011;123(21):­2373–2381

597. Mohammadi S, Kalavrouziotis D, Dagenais F, Voisine P, Charbonneau E. Completeness­of revascularization and survival among octogenarians with triple-vessel­disease. Ann Thorac Surg 2012;93(5):1432–1437

598. Yi G, Youn YN, Joo HC, Hong S, Yoo KJ. Association of incomplete revascularization­with long-term survival after off-pump coronary artery bypass grafting. J Surg­Res 2013;185(1):166–173

599. Rastan AJ,Walther T, FalkV,Kempfert J, Merk D, Lehmann S, Holzhey D, MohrFW Does reasonable incomplete surgical revascularization affect early or long-term­survival in patients with multivessel coronary artery disease receiving left internal­mammary artery bypass to left anterior descending artery? Circulation 2009;­120(11 Suppl):S70–77

600. Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, Yannopoulos D,­Brilakis ES. Outcomes after complete vs. incomplete revascularization of patients­with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled­in randomized clinical trials and observational studies. J Am Coll Cardiol­2013;62(16):1421–1431

601. Scott R, Blackstone EH, McCarthy PM, Lytle BW, Loop FD, White JA,­Cosgrove DM. Isolated bypass grafting of the left internal thoracic artery to the­left anterior descending coronary artery. J Thorac Cardiovasc Surg 2000;120(1):­173–184

602. Boylan MJ, LytleBW, Loop FD, Taylor PC, Borsh JA, Goormastic M, Cosgrove DM Surgical treatment of isolated left anterior descending coronary stenosis. Comparison­of left internal mammary artery and venous autograft at 18 to 20 years of­follow-up. J Thorac Cardiovasc Surg. 1994;107:657–662

603. Sabik JF 3rd, Blackstone EH, Gillinov AM, Banbury MK, Smedira NG, Lytle BW. Influence­of patient characteristics and arterial grafts on freedom from coronary reoperation J Thorac Cardiovasc Surg 2006;131(1):90–98

604. Schmitto JD, Rajab TK, Cohn LH. Prevalence and variability of internal mammary­graft use in contemporary multivessel coronary artery bypass graft. Curr Opin­Cardiol 2010;25(6):609–612

605. Taggart DP, D’Amico R, Altman DG. Effect of arterial revascularisation on survival:­a systematic review of studies comparing bilateral and single internal mammary arteries Lancet 2001;358(9285):870–875

606. Ruttmann E, Fischler N, Sakic A, Chevtchik O, Alber H, Schistek R, Ulmer H,­Grimm M. Second internal thoracic artery vs. radial artery in coronary artery­bypass grafting: a long-term, propensity score-matched follow-up study. Circulation­2011;124(12):1321–1329

607. Galbut DL, Kurlansky PA, Traad EA, Dorman MJ, Zucker M, Ebra G. Bilateral internal­thoracic artery grafting improves long-term survival in patients with reduced­ejection fraction: a propensity-matched study with 30-year follow-up. J Thorac Cardiovasc­Surg 2012;143(4):844–853 e4

608. Grau JB, Ferrari G, Mak AW, Shaw RE, Brizzio ME, Mindich BP, Strobeck J,­Zapolanski A. Propensity matched analysis of bilateral internal mammary artery­vs. single left internal mammary artery grafting at 17-year follow-up: validation of­a contemporary surgical experience. Eur J Cardiothorac Surg 2012;41(4):770–775,­discussion 776

609. LytleBW. Bilateral internal thoracic artery grafting. Ann Cardiothorac Surg 2013;2(4):­485–492

610. Weiss AJ, Zhao S, Tian DH, Taggart DP, Yan TD. A meta-analysis comparing bilateral­internalmammaryartery with left internalmammary artery for coronary artery­bypass grafting. Ann Cardiothorac Surg 2013;2(4):390–400

611. Hemo E, Mohr R, Uretzky G, Katz G, Popovits N, Pevni D, Medalion B. Long-term­outcomes of patients with diabetes receiving bilateral internal thoracic artery­grafts. J Thorac Cardiovasc Surg 2013;146(3):586–592

612. Taggart DP, Lees B, Gray A, Altman DG, Flather M, Channon K, Investigators ART Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to­compare survival following bilateral vs. single internal mammary grafting in coronary­revascularisation [ISRCTN46552265]. Trials 2006;7:7

613. Elmistekawy EM, Gawad N, Bourke M, Mesana T, Boodhwani M, Rubens FD. Is bilateral­internal thoracic artery use safe in the elderly? J Card Surg 2012;27(1):1–5

614. Toumpoulis IK, Theakos N, Dunning J. Does bilateral internal thoracic artery­harvest increase the risk of mediastinitis? Interact Cardiovasc Thorac Surg 2007;­6(6):787–791

615. Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM,Harris LJ, Stelzer P,CohenB,­Hoffman DM. Radial artery conduits improve long-term survival after coronary­artery bypass grafting. Ann Thorac Surg 2010;90(4):1165–1172

616. Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P,­Cohen BM, Ko W, DeCastro H, Lucido D, Hoffman DM. Coronary artery­bypass grafting using the radial artery: clinical outcomes, patency, and need for reintervention Circulation 2012;126(11 Suppl 1):S170–175

617. Schwann TA, Engoren M, Bonnell M, Clancy C, Habib RH. Comparison of late coronary­artery bypass graft survival effects of radial artery vs. saphenous vein grafting­in male and female patients. Ann Thorac Surg 2012;94(5):1485–1491

618. Hayward PA, Gordon IR, Hare DL, Matalanis G, Horrigan ML, Rosalion A,­Buxton BF. Comparable patencies of the radial artery and right internal thoracic­artery or saphenous vein beyond 5 years: results from the Radial Artery Patency­and Clinical Outcomes trial. J Thorac Cardiovasc Surg 2010;139(1):60–65; discussion­65–67

619. Kieser TM, Rose S, Kowalewski R, Belenkie I. Transit-time flow predicts outcomes­in coronary artery bypass graft patients: a series of 1000 consecutive arterial grafts Eur J Cardiothorac Surg 2010;38(2):155–162

620. Jokinen JJ,Werkkala K, Vainikka T, Perakyla T, Simpanen J, Ihlberg L. Clinical value of­intra-operative transit-time flow measurement for coronary artery bypass grafting:­a prospective angiography-controlled study. Eur J Cardiothorac Surg 2011;39(6):­918–923

621. Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, Straka Z,­Piegas LS, Akar AR, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC,­Novick RJ, Vaijyanath P, Reddy SK, Tao L, Olavegogeascoechea PA, Airan B,­Sulling TA, Whitlock RP, Ou Y, Pogue J, Chrolavicius S, Yusuf S, Investigators C Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N­Engl J Med 2013;368(13):1179–1188

622. Diegeler A, Borgermann J, Kappert U, Breuer M, Boning A, Ursulescu A, Rastan A,­Holzhey D, Treede H, Riess FC, Veeckmann P, Asfoor A, Reents W, Zacher M,­Hilker M. Off-pump vs. on-pump coronary-artery bypass grafting in elderly­patients. N Engl J Med 2013;368(13):1189–1198

623. Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC,­Baltz JH, Novitzky D. On-pump vs. off-pump coronary-artery bypass surgery N Engl J Med 2009;361(19):1827–1837

624. Houlind K, Kjeldsen BJ, Madsen SN, Rasmussen BS, Holme SJ, Nielsen PH,­Mortensen PE, Group DS. On-pump vs. off-pump coronary artery bypass­surgery in elderly patients: results from the Danish on-pump vs. off-pump randomization­study. Circulation 2012;125(20):2431–2439

625. Hattler B, Messenger JC, Shroyer AL, Collins JF, Haugen SJ, Garcia JA, Baltz JH,­Cleveland JC Jr., Novitzky D, Grover FL, Veterans Affairs Randomized On, /Off­Bypass Study G. Off-Pump coronary artery bypass surgery is associated with­worse arterial and saphenous vein graft patency and less effective revascularization:­Results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial. Circulation­2012;125(23):2827–2835

626. Sedrakyan A, Wu AW, Parashar A, Bass EB, Treasure T. Off-pump surgery is associated­with reduced occurrence of stroke and other morbidity as compared with­traditional coronary artery bypass grafting: a meta-analysis of systematically­reviewed trials. Stroke 2006;37(11):2759–2769

627. Keeling WB, Kilgo PD, Puskas JD, Halkos ME, Lattouf OM, Guyton RA,­Thourani VH. Off-pump coronary artery bypass grafting attenuates morbidity­and mortality for patients with low and high body mass index. J Thorac Cardiovasc­Surg 2012;146(6):1142–1148

628. Puskas JD, WilliamsWH,O’Donnell R, Patterson RE, Sigman SR, Smith AS, BaioKT,­Kilgo PD, Guyton RA. Off-pump and on-pump coronary artery bypass grafting are­associated with similar graft patency, myocardial ischemia, and freedom from reintervention:­long-term follow-up of a randomized trial. Ann Thorac Surg 2011;91(6):­1836–1842; discussion 1842–1843

629. Puskas JD, Thourani VH, Kilgo P, Cooper W, Vassiliades T, Vega JD, Morris C,­Chen E, Schmotzer BJ, Guyton RA, Lattouf OM. Off-pump coronary artery­bypass disproportionately benefits high-risk patients. Ann Thorac Surg 2009;88(4):­1142–1147

630. Head SJ, Borgermann J, Osnabrugge RL, Kieser TM, Falk V, Taggart DP, Puskas JD,­Gummert JF, Kappetein AP. Coronary artery bypass grafting: Part 2:optimizing outcomes­and future prospects. Eur Heart J 2013;34(37):2873–2886

631. Diegeler A,WaltherT, Metz S, FalkV, Krakor R, Autschbach R,MohrFW. Comparison­of MIDCAP vs. conventional CABG surgery regarding pain and quality of life Heart Surg Forum 1999;2(4):290–295; discussion 295–296

632. Groh MA, Sutherland SE, BurtonHG3rd, JohnsonAM, ElySW. Port-access coronary­artery bypass grafting: technique and comparative results. Ann Thorac Surg 1999;­68(4):1506–1508

633. Lapierre H, Chan V, Sohmer B, Mesana TG, Ruel M. Minimally invasive coronary­artery bypass grafting via a small thoracotomy vs. off-pump: a case-matched­study. Eur J Cardiothorac Surg 2011;40(4):804–810

634. Siregar S, Groenwold RH, de Mol BA, Speekenbrink RG, Versteegh MI, Brandon­Bravo Bruinsma GJ, Bots ML, van der Graaf Y, van Herwerden LA. Evaluation of­cardiac surgery mortality rates: 30-day mortality or longer follow-up? Eur J Cardiothorac­Surg 2013;44(5):875–883

635. Peterson ED, Coombs LP, DeLong ER, Haan CK, Ferguson TB. Procedural volume­as a marker of quality for CABG surgery. JAMA 2004;291(2):195–201

636. Sergeant P, Blackstone E, Meyns B. Validation and interdependence with patientvariables­of the influence of procedural variables on early and late survival after­CABG. K.U. Leuven Coronary Surgery Program. Eur J Cardiothorac Surg 1997;­12(1):1–19

637. Williams JB, Peterson ED, Brennan JM, Sedrakyan A, Tavris D, Alexander JH,­Lopes DR, Dokholyan RS, Zhao Y, O’Brien SM, Michler RE, Thourani VH,­Edwards FH, Duggirala H, Gross T, Marinac-Dabic D, Smith PK. Association­Between Endoscopic vs.Open Vein-Graft Harvesting and Mortality,Wound Complications,­and Cardiovascular Events in Patients Undergoing CABG Surgery. JAMA­2012;308:(5):475–484

638. Bakaeen FG. Endoscopic vein harvest for coronary artery bypass grafting is safe J Surg Res 2013;185(2):522–523

639. Schmitto JD, Rajab TK, Cohn LH. Prevalence and variability of internal mammary­graft use in contemporary multivessel coronary artery bypass graft. Curr Opin­Cardiol 2010;25:609–612

640. Dorman MJ, Kurlansky PA, Traad EA, Galbut DL, Zucker M, Ebra G. Bilateral Internal­Mammary Artery Grafting Enhances Survival in Diabetic Patients: A 30-Year­Follow-Up of Propensity Score 2Matched Cohorts. Circulation 2012;126:­2935–2942

641. Kieser TM, LewinAM, Graham MM, Martin BJ, Galbraith PD, Rabi DM, Norris CM,­Faris PD, Knudtson ML, GhaliWA, Investigators A. Outcomes associated with bilateral­internal thoracic artery grafting: the importance of age. Ann Thorac Surg 2011;­92(4):1269–1275; discussion 1275–1276

642. Desai ND, Cohen EA, Naylor CD, Fremes SE. A Randomized Comparison of­Radial-Artery and Saphenous-Vein Coronary Bypass Grafts. N Engl J Med 2004;­351:2302–2309

643. Tatoulis J. Total arterial coronary revascularization-patient selection, stenoses,­conduits, targets. Ann Cardiothorac Surg 2013;2(4):499–506

644. Borgermann J, Hakim K, Renner A, Parsa A, Aboud A, Becker T, Masshoff M,­Zittermann A,Gummert JF, Kuss O. Clampless off-pump vs. conventional coronary­artery revascularization: a propensity score analysis of 788 patients. Circulation­2012;126(11 Suppl 1):S176–182

645. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical­bayesian meta-analysis. Ann Intern Med 2003;138(10):777–786

646. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ,­Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A. Intracoronary stenting and­angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO)­trial. Circulation 2001;103(23):2816–2821

647. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M,­Neumann FJ, Sattelberger U, Schmitt C, Muller M, Dirschinger J, Schomig A. Intracoronary­stenting and angiographic results: strut thickness effect on restenosis­outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41(8):1283–1288

648. Mehran R, Baber U, Steg PG, Ariti C,Weisz G, Witzenbichler B, Henry TD, Kini AS,­Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G,Waksman R, Antoniucci D,­Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M,­Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment­and cardiac events after percutaneous coronary intervention (PARIS): 2 year­results from a prospective observational study. Lancet 2013;382(9906):­1714–1722

649. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M,­Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A. Analysis­of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J­Med 2007;356(10):1030–1039

650. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A,­Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R,­Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 2007;356(10):998–1008

651. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N,­Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B,­Windecker S, Serruys PW. Early and late coronary stent thrombosis of­sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data­from a large two-institutional cohort study. Lancet 2007;369(9562):667–678

652. De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der­Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la­Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H,­Stone GW. Drug-eluting vs.bare-metal stents in primary angioplasty: a pooled­patient-level meta-analysis of randomized trials. Arch Intern Med 2012;172(8):­611–621, discussion 621–622

653. Nabel EG, Braunwald E.Atale of coronary artery disease and myocardial infarction N Engl J Med 2012;366(1):54–63

654. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J,­Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ Everolimus-eluting vs. paclitaxel-eluting stents in coronary artery disease. N Engl­J Med 2010;362(18):1663–1674

655. SerruysPW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van­Boven AJ, Hofma SH, Linke A, Klauss V, WijnsW, Macaya C, Garot P, DiMario C,­Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M,­Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of­zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;­363(2):136–146

656. Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN,­Kaltoft A, Maeng M, Kristensen SD, Botker HE, Terkelsen CJ, Villadsen AB,­Ravkilde J, Aaroe J, Madsen M, Thuesen L, Lassen JF. Biolimus-eluting biodegradable­polymer-coated stent vs. durable polymer-coated sirolimus-eluting stent in unselected­patients receiving percutaneous coronary intervention (SORT OUT V): a­randomised non-inferiority trial. Lancet 2013;381(9867):661–669

657. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S,­Pache J, Fusaro M, Seyfarth M, Schomig A, Mehilli J. Randomized, non-inferiority­trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary­Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting­Stents (ISAR-TEST-4) Trial. Eur Heart J 2009;30(20):2441–2449

658. Smits PC, Hofma S, Togni M, Vazquez N, Valdes M, Voudris V, Slagboom T, Goy JJ,­Vuillomenet A, Serra A, Nouche RT, den Heijer P, van der Ent M. Abluminal biodegradable­polymer biolimus-eluting stent vs. durable polymer everolimus-eluting­stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;­381(9867):651–660

659. Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, IbrahimT, Fusaro M,­Ott I, Schomig A, Laugwitz KL, Mehilli J. Polymer-free sirolimus- and­probucol-eluting vs. new generation zotarolimus-eluting stents in coronary­artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy­of Sirolimus- and Probucol-Eluting vs. Zotarolimus-eluting Stents (ISAR-TEST 5)­trial. Circulation 2011;124(5):624–632

660. Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, Christians U, Betts R,­Savage D, Su SH, Shulze J, Kar S. Polymer-free biolimus a9-coated stent demonstrates­more sustained intimal inhibition, improved healing, and reduced inflammation­compared with a polymer-coated sirolimus-eluting cypher stent in a porcine­model. Circ Cardiovasc Interv 2010;3(2):174–183

661. Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, Serruys PW, StoneGW Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and­stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation­of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A­Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization­in Daily Practice) Trials. JACC Cardiovasc Interv 2011;4(10):1104–1115

662. ParkKW, Kang SH, Velders MA, Shin DH, Hahn S, Lim WH, Yang HM, Lee HY, Van­Boven AJ, Hofma SH, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Kim HS Safety and efficacy of everolimus- vs. sirolimus-eluting stents: a systematic review­and meta-analysis of 11 randomized trials. Am Heart J 2013;165(2):241–250 e4

663. HawnMT, Graham LA, Richman JS, Itani KM, HendersonWG, Maddox TM. Risk of­major adverse cardiac events following noncardiac surgery in patients with coronary­stents. JAMA 2013;310(14):1462–1472

664. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J,­Hagiwara N, Allocco DJ, Dawkins KD. A prospective, randomized evaluation of a­novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized,­Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System­[PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery­Lesions) trial. J Am Coll Cardiol 2011;57(16):1700–1708

665. von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van­Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH,­Stoel MG, Lowik MM, Linssen GC, Said SA, Nienhuis MB, Verhorst PM,­Basalus MW, Doggen CJ, Tandjung K. Third-generation zotarolimus-eluting and­everolimus-eluting stents in all-comer patients requiring a percutaneous coronary­intervention (DUTCH PEERS): a randomised, single-blind, multicentre, noninferiority­trial. Lancet 2013;383(9915):413–423

666. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG,­Louwerenburg JH, Linssen GC, Said SA, Kleijne MA, Sen H, Lowik MM, van der­Palen J, Verhorst PM, de Man FH. A randomized controlled trial in secondgeneration­zotarolimus-eluting Resolute stents vs. everolimus-eluting Xience V­stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012;59(15):­1350–1361

667. Kedhi E, Joesoef KS, McFadden E,Wassing J, van MieghemC, Goedhart D, Smits PC Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life­practice (COMPARE): a randomised trial. Lancet 2010;375(9710):201–209

668. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K,­Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C,­Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P. Biolimus-eluting­stent with biodegradable polymer vs. sirolimus-eluting stent with durable­polymer for coronary revascularisation (LEADERS): a randomised non-inferiority­trial. Lancet 2008;372(9644):1163–1173

669. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y,­Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M,­Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y,­Shiode N, Kimura T. Biodegradable polymer biolimus-eluting stent vs. durable­polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J­Am Coll Cardiol 2013;62(3):181–190

670. Serruys PW, Garg S, Abizaid A, Ormiston J, Windecker S, Verheye S, Dubois C,­Stewart J, Hauptmann KE, Schofer J, Stangl K, Witzenbichler B, Wiemer M,­Barbato E, de Vries T, den Drijver AM, Otake H, Meredith L, Toyloy S,­Fitzgerald P. A randomised comparison of novolimus-eluting and zotarolimuseluting­coronary stents: 9-month follow-up results of the EXCELLA II study. Euro-­Intervention 2010;6(2):195–205

671. Verheye S, Ramcharitar S, Grube E, Schofer JJ, Witzenbichler B, Kovac J,­Hauptmann KE, Agostoni P, Wiemer M, Lefevre T, Spaargaren R, Serruys PW,­Garcia-Garcia HM, van Geuns RJ. Six-month clinical and angiographic results of­the STENTYS(R) self-apposing stent in bifurcation lesions. EuroIntervention 2011;­7(5):580–587

672. Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, Trauthen B,­Hasegawa T, Koo BK, Fitzgerald PJ, Mehran R, Lansky AJ. 9-month clinical, angiographic,­and intravascular ultrasound results of a prospective evaluation of the­Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions:­the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively)­study. J Am Coll Cardiol 2009;53(12):1031–1039

673. Buysschaert I, Dubois CL, Dens J, Ormiston J, Worthley S, McClean D,­Ottervanger JP, Meredith I, Uren N, Wijns W, Whitbourn R, Mehran R,­Lansky AJ, Bichalska M, Meis S, Verheye S. Three-year clinical results of the­Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention­2013;9(5):573–581

674. Dani S, Costa RA, Joshi H, Shah J, Pandya R, Virmani R, Sheiban I, Bhatt S, Abizaid A First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent­with bioabsorbable polymer for the treatment of single de novo lesions located­in native coronary vessels - results from the meriT-1 trial. EuroIntervention 2013;­9(4):493–500

675. Haude M, Lee SW,Worthley SG, Silber S, Verheye S, Erbs S, Rosli MA, Botelho R,­Meredith I, Sim KH, Stella PR, Tan HC, Whitbourn R, Thambar S, Abizaid A,­Koh TH, Den Heijer P, Parise H, Cristea E, Maehara A, Mehran R. The REMEDEE­trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor­cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv 2013;­6(4):334–343

676. Vranckx P, SerruysPW, Gambhir S, Sousa E, Abizaid A, Lemos P, Ribeiro E, Dani SI,­Dalal JJ, Mehan V, Dhar A, Dutta AL, Reddy KN, Chand R, Ray A, Symons J Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical­and angiographic follow-up results from the SIMPLE II prospective multi-centre­registry study. EuroIntervention 2006;2(3):310–317

677. Ormiston J,Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C,­Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, WijnsW. First-in-Human Evaluation­of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent: Imaging and­Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable­Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary­Arteries). JACC Cardiovasc Interv 2013;6(10):1026–1034

678. Dani S, Kukreja N, Parikh P, Joshi H, Prajapati J, Jain S, Thanvi S, Shah B, Dutta JP Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic,­30-month clinical follow-up results from the series I prospective study EuroIntervention 2008;4(1):59–63

679. Seth A, Chandra P, Chouhan NS, Thakkar AS. A first-in-man study of­sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real­life patients. Indian Heart J 2012;64(6):547–552

680. Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carrie D, Walsh S,­Oldroyd KG, Varenne O, El-Jack S, Moreno R, Joshi AA, Allocco DJ,­Dawkins KD. Primary endpoint results of the EVOLVE trial: a randomized evaluation­of a novel bioabsorbable polymer-coated, everolimus-eluting coronary­stent. J Am Coll Cardiol 2012;59(15):1362–1370

681. Carrie D, Berland J, Verheye S, Hauptmann KE, Vrolix M, Violini R, Dibie A, Berti S,­Maupas E, Antoniucci D, Schofer J. A multicenter randomized trial comparing­amphilimus- with paclitaxel-eluting stents in de novo native coronary artery­lesions. J Am Coll Cardiol 2012;59(15):1371–1376

682. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J,­Schomig A. Randomized trial of a nonpolymer-based rapamycin-eluting stent vs a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation­2006;113(2):273–279

683. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schomig A, Kastrati A. Durability­of antirestenotic efficacy in drug-eluting stents with and without permanent­polymer. JACC Cardiovasc Interv 2009;2(4):291–299

684. Garg S, Bourantas C, SerruysPW. New concepts in the design of drug-eluting coronary­stents. Nat Rev Cardiol 2013;10(5):248–260

685. Ormiston JA, SerruysPW, Regar E, Dudek D, Thuesen L,WebsterMW, Onuma Y,­Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting­coronary stent system for patients with single de-novo coronary artery lesions­(ABSORB): a prospective open-label trial. Lancet 2008;371(9616):899–907

686. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM,­Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M,­Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system­(ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet­2009;373(9667):897–910

Не нашли, что искали? Воспользуйтесь поиском: